Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2001

View Archived Issues

Active Biotech discusses progress during 2000

Nastech reports corporate update

Ferring initiates optimal drug protocol trial for IVF treatment

Enrollment complete in Angiotech phase II study of micellar paclitaxel for SPMS

Millennium begins phase II clinical trial of LDP-341 for treatment of multiple myeloma

FDA cancels advisory committee review of Xyrem NDA

BioMarin completes enrollment in clinical trials of MPS-I and MPS-VI treatments

First clinical study of acyline, a potent and long-acting GnRH antagonist

High contraceptive potency and excellent safety reported for microemulsion-based vaginal spermicide

Arglabin-DMA acts as an inhibitor of posttranslational processing of Ras protein

Cortez Development acquires MoliChem Medicines and changes name

Genomics collaboration between Pharmagene and Bayer expanded

Optimal dose range of pentasaccharide factor Xa inhibitor and comparison to LMWH

CPMP issues positive opinion for new NeoRecormon indication

New safety data added to Zyvox prescribing information

VENUS trial results do not support use of early nimodipine in stroke

Introgen's INGN-241 shows antitumor activity against human melanoma

GlaxoSmithKline and WHO to develop new treatment for malaria

Profile of new antiparkinsonian agent SLV-308 up to early clinical studies

Faulding to market and sell NaPro's paclitaxel in Europe

Aventis's new vector complexes useful in gene therapy of cancer

Antitumor phosphoramide compounds designed at Purdue

New GH secretagogues in development at Merck

Cephalosporins synthesized at Roche and tested for antibacterial activity

Protein kinase inhibitors and their use in the treatment of cancer presented by Agouron

Novel Nippon Kayaku compounds inhibit tumor cell proliferation

Benzazepinones and quinazolines useful for cancer, osteoporosis, etc., according to Roche

Mochida's factor Xa inhibitors endowed with in vivo anticoagulant activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...